These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
427 related items for PubMed ID: 30563350
1. 68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. Nandurkar R, van Leeuwen P, Stricker P, Woo H, Kooner R, Yuen C, O'Neill G, Ende D, Cusick T, Ho B, Hickey A, Emmett L. Br J Radiol; 2019 Mar; 92(1095):20180667. PubMed ID: 30563350 [Abstract] [Full Text] [Related]
2. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW. BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748 [Abstract] [Full Text] [Related]
3. Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P. J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524 [Abstract] [Full Text] [Related]
4. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [Abstract] [Full Text] [Related]
5. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer. van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L. BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667 [Abstract] [Full Text] [Related]
6. 68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer. Pfister D, Haidl F, Nestler T, Verburg F, Schmidt M, Wittersheim M, Steib F, Heidenreich A. BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840 [Abstract] [Full Text] [Related]
7. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469 [Abstract] [Full Text] [Related]
8. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J. World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332 [Abstract] [Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Dec; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
10. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C. Radiat Oncol; 2018 Mar 02; 13(1):37. PubMed ID: 29499730 [Abstract] [Full Text] [Related]
11. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H. J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970 [Abstract] [Full Text] [Related]
12. 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. Emmett L, Tang R, Nandurkar R, Hruby G, Roach P, Watts JA, Cusick T, Kneebone A, Ho B, Chan L, van Leeuwen PJ, Scheltema MJ, Nguyen A, Yin C, Scott A, Tang C, McCarthy M, Fullard K, Roberts M, Francis R, Stricker P. J Nucl Med; 2020 Jun 07; 61(6):866-872. PubMed ID: 31676727 [Abstract] [Full Text] [Related]
13. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M. Eur Urol; 2018 May 07; 73(5):656-661. PubMed ID: 29358059 [Abstract] [Full Text] [Related]
14. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses. Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F. Urol Oncol; 2022 Jan 07; 40(1):6.e1-6.e9. PubMed ID: 34400066 [Abstract] [Full Text] [Related]
15. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D. J Urol; 2019 Apr 07; 201(4):815-820. PubMed ID: 30672842 [Abstract] [Full Text] [Related]
16. The diagnostic accuracy of 68 Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis. Rajwa P, Heidenreich J, Drzezga A, Schmidt M, Shariat SF, Heidenreich A. Prostate; 2024 Jan 07; 84(1):74-78. PubMed ID: 37750292 [Abstract] [Full Text] [Related]
17. Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy. Spena G, Moretti TB, Dávila FS, Dos Anjos G, Khan I, Calace FP, Aveta A, Pandolfo SD, Tufano A, Izzo A, Farias A, Perdonà S, Maes K. Minerva Urol Nephrol; 2024 Aug 07; 76(4):467-473. PubMed ID: 39051893 [Abstract] [Full Text] [Related]
18. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C. Eur Urol; 2016 Mar 07; 69(3):393-6. PubMed ID: 26116958 [Abstract] [Full Text] [Related]
19. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI. Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M. Mol Imaging Biol; 2022 Feb 07; 24(1):50-59. PubMed ID: 34519966 [Abstract] [Full Text] [Related]
20. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters. Mazzone E, Gandaglia G, Robesti D, Rajwa P, Gomez Rivas J, Ibáñez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Moreno Sierra J, Porpiglia F, Picchio M, Chiti A, van den Bergh R, Shariat SF, Montorsi F, Briganti A. Eur Urol Oncol; 2024 Apr 07; 7(2):231-240. PubMed ID: 37689506 [Abstract] [Full Text] [Related] Page: [Next] [New Search]